“ Estradiol 17beta reduces coronary artery constriction following methylergometrine administration in menopausal patients with coronary artery disease.”
“However, the degree of coronary artery constriction after maximal doses of methylergometrine was significantly attenuated by estradiol 17beta compared to placebo (change in diameter: -0.9+/-4.5% vs. -19+/-6%, p<0.001; change in area: -3.2+/-9% vs. -32.2+/-10%, p<0.001).”